Regulation of urokinase receptor function and pericellular proteolysis by the integrin α5β1

Rosemary Bass; Vincent Ellis

doi:10.1160/TH08-08-0558

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2009; 101(05): 954-962
DOI: 10.1160/TH08-08-0558

Cellular Proteolysis and Oncology

Schattauer GmbH

Regulation of urokinase receptor function and pericellular proteolysis by the integrin α₅β₁

Rosemary Bass

¹School of Biological Sciences, University of East Anglia, Norwich, United Kingdom

,

Vincent Ellis

¹School of Biological Sciences, University of East Anglia, Norwich, United Kingdom

› Institutsangaben

Abstract

Summary

Interactions between the uPA receptor (uPAR) and various inte-grins, including α₅β₁, are known to modulate integrin-dependent cell adhesion, and we have shown that the integrin-associated tetraspanin protein CD82 down-regulates uPAR-dependent plasminogen activation by affecting α₅β₁ cellular localisation. Here we have investigated whether overexpression of α₅β₁ directly affects uPAR-dependent pericellular proteolysis. CHO cells overexpressing α₅β₁ were found to activate plasminogen at a rate up to 18-fold faster than B2CHO cells which are α₅-deficient. This effect was dependent on the activation state of α₅β₁, as it was maximal in the presence of Mn²⁺. To determine the role of uPAR-α₅β₁ interactions in this effect, we determined the adhesion of these cells to immobilised soluble uPAR (suPAR). Neither cell-type was found to adhere to suPAR, but both cell types were found to adhere to an anti-uPAR monoclonal antibody in a uPAR- and integrin-dependent manner. This adhesion was 10-fold greater in the absence of α₅β₁, possibly implicating the involvement of non-α₅-integrins. Soluble forms of the various components were used to investigate the molecular basis of these effects, but no direct interactions could be demonstrated between α₅β₁ and either uPAR, uPA or uPA-uPAR complex. This suggests that assembly of these components on the plasma membrane is required to influence uPAR function, increasing uPAR-dependent pericellular proteolysis and decreasing uPAR-dependent cell adhesion. These interactions may be modified by other integrins, suggesting a complex interplay between uPAR and integrins on the cell surface with the potential to regulate invasive cell migration.

Keywords

uPA - uPAR - plasminogen activation - integrins - cell adhesion

Volltext

Referenzen

References
1 Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-2188.
2 Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758.
3 Zhou HM, Nichols A, Meda P. et al. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000; 19: 4817-4826.
4 Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-17984.
5 Ellis V, Murphy G. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett 2001; 506: 1-5.
6 Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol 2003; 54: 263-312.
7 Bass R, Ellis V. Cellular mechanisms regulating non-haemostatic plasmin generation. Biochem Soc Trans 2002; 30: 189-194.
8 Wei Y, Lukashev M, Simon DI. et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
9 Simon DI, Wei Y, Zhang L. et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-10234.
10 Wei Y, Eble JA, Wang Z. et al. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol Biol Cell 2001; 12: 2975-2986.
11 Monaghan E, Gueorguiev V, Wilkins-Port C. et al. The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts. J Biol Chem 2004; 279: 1400-1407.
12 Wei Y, Czekay RP, Robillard L. et al. Regulation of α5β1 integrin conformation and function by urokinase receptor binding. J Cell Biol 2005; 168: 501-511.
13 Wei Y, Waltz DA, Rao N. et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
14 Okumura Y, Kamikubo Y, Curriden SA. et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 2002; 277: 9395-9404.
15 Sidenius N, Andolfo A, Fesce R. et al. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 2002; 277: 27982-27990.
16 Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
17 Aguirre-Ghiso JA, Liu D, Mignatti A. et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001; 12: 863-879.
18 Tarui T, Andronicos N, Czekay RP. et al. Critical role of integrin α5β1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem 2003; 278: 29863-29872.
19 Wei Y, Tang CH, Kim Y. et al. Urokinase receptors are required for α5β1 integrin-mediated signaling in tumor cells. J Biol Chem 2007; 282: 3929-3939.
20 Bass R, Werner F, Odintsova E. et al. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 2005; 280: 14811-14818.
21 Sechler JL, Corbett SA, Schwarzbauer JE. Modula-tory roles for integrin activation and the synergy site of fibronectin during matrix assembly. Mol Biol Cell 1997; 08: 2563-2573.
22 Schreiner CL, Bauer JS, Danilov YN. et al. Isolation and characterization of Chinese hamster ovary cell variants deficient in the expression of fibronectin receptor. J Cell Biol 1989; 109: 3157-3167.
23 Coe AP, Askari JA, Kline AD. et al. Generation of a minimal α5β1 integrin-Fc fragment. J Biol Chem 2001; 276: 35854-35866.
24 Rønne E, Behrendt N, Ellis V. et al. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2– terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-236.
25 Messent AJ, Tuckwell DS, Knauper V. et al. Effects of collagenase-cleavage of type I collagen on α2β1 integrin-mediated cell adhesion. J Cell Sci 1998; 111: 1127-1135.
26 Liou AK, Willison KR. Elucidation of the subunit orientation in CCT (chaperonin containing TCP1) from the subunit composition of CCT micro-complexes. EMBO J 1997; 16: 4311-4316.
27 Bazzoni G, Ma L, Blue ML. et al. Divalent cations and ligands induce conformational changes that are highly divergent among β1 integrins. J Biol Chem 1998; 273: 6670-6678.
28 Mould AP, Garratt AN, Puzon-McLaughlin W. et al. Regulation of integrin function: evidence that bivalentcation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin α5β1. Biochem J 1998; 331: 821-828.
29 Tarui T, Mazar AP, Cines DB. et al. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983-3990.
30 Elsasser S, Schmidt M, Finley D. Characterization of the proteasome using native gel electrophoresis. Methods Enzymol 2005; 398: 353-363.
31 Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin αMβ₂ as well as by the urokinase receptor regulates cell adhesion and migration. Blood 2003; 101: 1582-1590.
32 Pluskota E, Soloviev DA, Bdeir K. et al. Integrin αMβ₂ orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 18063-18072.
33 Tarui T, Akakura N, Majumdar M. et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin αvβ3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95: 524-534.
34 Harris TJ, Siu CH. Reciprocal raft-receptor interactions and the assembly of adhesion complexes. Bioes-says 2002; 24: 996-1003.
35 Yebra M, Goretzki L, Pfeifer M. et al. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 1999; 250: 231-240.
36 Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001; 114: 4143-4151.
37 Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003; 19: 397-422.
38 Yuan C, Huang M. Does the urokinase receptor exist in a latent form?. Cell Mol Life Sci 2007; 64: 1033-1037.
39 Llinas P, Le Du MH, Gardsvoll H. et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-1663.
40 Huang M, Mazar AP, Parry G. et al. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1–143). Acta Crystallogr D Biol Crystallogr 2005; 61: 697-700.
41 Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase- type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom α-neurotoxins. FEBS Lett 1994; 349: 163-168.
42 Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991-8997.
43 List K, Høyer-Hansen G, Rønne E. et al. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 1999; 222: 125-133.